HMGN2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical carcinoma line, providing a loss-of-function model for studying the nucleosome-binding protein HMGN2. This heterogeneous pool of gene-disrupted cells facilitates investigation of HMGN2??s role in chromatin organization and transcriptional control. The product is a robust tool for functional genomics, enabling interrogation of HMGN2-dependent mechanisms in an epithelial cancer context. This polyclonal population avoids clonal artifacts and captures a spectrum of editing outcomes, offering a more representative model for population-level studies.
HeLa cells are an immortalized human epithelial line derived from cervical adenocarcinoma, extensively used in cancer biology, signal transduction, and drug discovery. Their rapid growth, ease of genetic manipulation, and well-characterized signaling pathways make them an ideal host for knockout studies. In this polyclonal HMGN2 knockout population, the cells retain the parental line??s core features while introducing targeted loss of gene function, enabling analysis of phenotypic heterogeneity caused by defective HMGN2.
HMGN2 encodes a nucleosome-binding protein that competes with Histone H1 and interacts with the FACT complex to decompact chromatin, increasing transcription factor accessibility. In Wnt signaling, HMGN2 acts downstream of ???catenin/TCF complexes and promotes expression of target genes such as c?Myc and Cyclin D1. Wnt ligands, through Frizzled receptors and DVL activation, stabilize ???catenin, which transcriptionally upregulates HMGN2. HMGN2 then facilitates open chromatin at Wnt?responsive loci, coupling signal transduction to local nucleosome remodeling.
Within the HeLa cervical carcinoma background, HMGN2 loss is predicted to elevate chromatin compaction, dampen Wnt?dependent transcription, and impair nucleosome mobility. HeLa cells express HPV oncoproteins that already disrupt chromatin regulation, so ablating HMGN2 offers a platform to dissect the combined effects of viral transformation and host chromatin remodeling on cancer phenotypes. This polyclonal knockout model allows examination of how heterogeneous HMGN2 deficiency influences oncogenic signaling, DNA repair, and proliferation, better mimicking the genetic variation seen in tumors.
Researchers can utilize this polyclonal knockout cell pool in assorted functional assays, including Western blotting and RT?qPCR to confirm HMGN2 depletion, RNA?seq for transcriptome profiling, ChIP?qPCR to map histone modifications at Wnt target loci, and immunofluorescence to observe chromatin decompaction defects. Complementary cell-based assays such as proliferation, colony formation, and cell cycle analysis link HMGN2 status to cancer cell fitness. The model also suits chemical screening for modulators of chromatin-dependent transcription or synthetic lethal vulnerabilities. For lot-specific details, please contact Ascent Research.
